Akèy › Limfom zòn marenal › Massachusetts
Etid klinik pou Limfom zòn marenal nan Massachusetts
12 etid pou Limfom zòn marenal ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07231952A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Lahey Clinic, Burlington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT06026319Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06510309Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 30, 2026 · NCT04669171AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 5, 2025 · NCT06986174SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.